BEAM or BuCyE high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: A single center comparative analysis of efficacy and toxicity

Leukemia Research

Volumn 35, Issue 2, 2011, Pages 183-187

  Kim, Jeong Eun ^a   Lee, Dae Ho ^a   Yoo, Changhoon ^a   Kim, Shin ^a   Kim, Sang We ^a   Lee, Jung Shin ^a   Park, Chan Jeong ^a   Huh, Jooryung ^a   Suh, Cheolwon ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

ASCT; BEAM; BuCyE; High dose chemotherapy; Non Hodgkin's lymphoma

Indexed keywords

BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; MELPHALAN;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CD34 SELECTION; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; ENGRAFTMENT; EVENT FREE SURVIVAL; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NAUSEA; NEUTROPHIL COUNT; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; SEPTICEMIA; THROMBOCYTE COUNT; TREATMENT OUTCOME; VEIN OCCLUSION; VOMITING;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DISEASE-FREE SURVIVAL; ETOPOSIDE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOMA, NON-HODGKIN; MALE; MELPHALAN; MIDDLE AGED; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78751705648     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.07.016     Document Type: Article

References (30)

1. Gianni A.M., Bregni M., Siena S., Brambilla C., Di Nicola M., Lombardi F., et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 1997, 336:1290-1297.
2. Haioun C., Lepage E., Gisselbrecht C., Bastion Y., Coiffier B., Brice P., et al. Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective study LNH87-2. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 1997, 15:1131-1137.
3. Salar A., Sierra J., Gandarillas M., Caballero M.D., Marin J., Lahuerta J.J., et al. Autologous stem cell transplantation for clinically aggressive non-Hodgkin's lymphoma: the role of preparative regimens. Bone Marrow Transplant 2001, 27:405-412.
4. Milpied N., Deconinck E., Gaillard F., Delwail V., Foussard C., Berthou C., et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 2004, 350:1287-1295.
5. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993, 329:987-994.
6. Mounier N., Gisselbrecht C. Conditioning regimens before transplantation in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol 1998, 9:S15-21.
7. Copelan E.A., Penza S.L., Pohlman B., Avalos B.R., Goormastic M., Andresen S.W., et al. Autotransplantation following busulfan, etoposide and cyclophosphamide in patients with non-Hodgkin's lymphoma. Bone Marrow Transplant 2000, 25:1243-1248.
8. Santos G.W., Tutschka P.J., Brookmeyer R., Saral R., Beschorner W.E., Bias W.B., et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med 1983, 309:1347-1353.
9. Weaver C.H., Schwartzberg L., Rhinehart S., West J., Zhen B., West W.H., et al. High-dose chemotherapy with BUCY or BEAC and unpurged peripheral blood stem cell infusion in patients with low-grade non-Hodgkin's lymphoma. Bone Marrow Transplant 1998, 21:383-389.
10. Hanel M., Kroger N., Sonnenberg S., Bornhauser M., Kruger W., Kroschinsky F., et al. Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma. Ann Hematol 2002, 81:96-102.
11. Kim J.G., Sohn S.K., Chae Y.S., Yang D.H., Lee J.J., Kim H.J., et al. Multicenter study of intravenous busulfan, cyclophosphamide, and etoposide (i.v. Bu/Cy/E) as conditioning regimen for autologous stem cell transplantation in patients with non-Hodgkin's lymphoma. Bone Marrow Transplant 2007, 40:919-924.
12. Kroger N., Hoffknecht M., Hanel M., Kruger W., Zeller W., Stockschlader M., et al. Busulfan, cyclophosphamide and etoposide as high-dose conditioning therapy in patients with malignant lymphoma and prior dose-limiting radiation therapy. Bone Marrow Transplant 1998, 21:1171-1175.
13. Buser A.S., Stern M., Bucher C., Arber C., Heim D., Halter J., et al. High-dose chemotherapy using BEAM without autologous rescue followed by reduced-intensity conditioning allogeneic stem-cell transplantation for refractory or relapsing lymphomas: a comparison of delayed versus immediate transplantation. Bone Marrow Transplant 2007, 39:335-340.
14. Caballero M.D., Rubio V., Rifon J., Heras I., Garcia-Sanz R., Vazquez L., et al. BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors. Bone Marrow Transplant 1997, 20:451-458.
15. Jang G., Ko O.B., Kim S., Lee D.H., Huh J., Suh C. Prospective randomized comparative observation of single- versus split-dose lenograstim to enhance engraftment after autologous stem cell transplantation in patients with multiple myeloma or non-Hodgkin's lymphoma. Transfusion 2008, 48:640-646.
16. Jo J.C., Kang B.W., Jang G., Sym S.J., Lee S.S., Koo J.E., et al. BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: comparative analysis of efficacy and toxicity. Ann Hematol 2008, 87:43-48.
17. Kim M.K., Kim S., Lee S.S., Sym S.J., Lee D.H., Jang S., et al. High-dose chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: complete response at transplant predicts survival. Ann Hematol 2007, 86:435-442.
18. Kim S., Kim H.J., Park J.S., Lee J., Chi H.S., Park C.J., et al. Prospective randomized comparative observation of single- vs. split-dose lenograstim to mobilize peripheral blood progenitor cells following chemotherapy in patients with multiple myeloma or non-Hodgkin's lymphoma. Ann Hematol 2005, 84:742-747.
19. Kim M.K., Kim S., Jang G., Lee S.S., Sym S.J., Lee D.H., et al. A randomized comparison of peripheral blood hematopoietic progenitor cell level of 5/mm versus 50/mm as a surrogate marker to initiate efficient autologous blood stem cell collection. J Clin Apher 2007, 22:277-282.
20. Kim M.K., Kim S., Lee S.S., Sym S.J., Lee D.H., Kim S.W., et al. Rituximab-ESHAP as a mobilization regimen for relapsed or refractory B-cell lymphomas: a comparison with ESHAP. Transfusion 2007, 47:1447-1454.
21. Cheson B.D., Horning S.J., Coiffier B., Shipp M.A., Fisher R.I., Connors J.M., et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999, 17:1244.
22. Wang E.H., Chen Y.A., Corringham S., Bashey A., Holman P., Ball E.D., et al. High-dose CEB vs. BEAM with autologous stem cell transplant in lymphoma. Bone Marrow Transplant 2004, 34:581-587.
23. Zaucha R., Gooley T., Holmberg L., Gopal A.K., Press O., Maloney D., et al. High-dose chemotherapy with BEAM or Busulphan/Melphalan and Thiotepa followed by hematopoietic cell transplantation in malignant lymphoma. Leuk Lymphoma 2008, 49:1899-1906.
24. Jantunen E., Kuittinen T., Nousiainen T. BEAC or BEAM for high-dose therapy in patients with non-Hodgkin's lymphoma? A single centre analysis on toxicity and efficacy. Leuk Lymphoma 2003, 44:1151-1158.
25. Bhatia S., Robison L.L., Francisco L., Carter A., Liu Y., Grant M., et al. Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the Bone Marrow Transplant Survivor Study. Blood 2005, 105:4215-4222.
26. Seshadri T., Pintilie M., Kuruvilla J., Keating A., Tsang R., Zadeh S., et al. Incidence and risk factors for second cancers after autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Leuk Lymphoma 2009, 50:380-386.
27. Grochow L.B., Jones R.J., Brundrett R.B., Braine H.G., Chen T.L., Saral R., et al. Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol 1989, 25:55-61.
28. Copelan E.A., Bechtel T.P., Avalos B.R., Elder P.J., Ezzone S.A., Scholl M.D., et al. Busulfan levels are influenced by prior treatment and are associated with hepatic veno-occlusive disease and early mortality but not with delayed complications following marrow transplantation. Bone Marrow Transplant 2001, 27:1121-1124.
29. Kashyap A., Wingard J., Cagnoni P., Roy J., Tarantolo S., Hu W., et al. Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD). HVOD-related mortality, and overall 100-day mortality. Biol Blood Marrow Transplant 2002, 8:493-500.
30. Wadehra N., Farag S., Bolwell B., Elder P., Penza S., Kalaycio M., et al. Long-term outcome of Hodgkin disease patients following high-dose busulfan, etoposide. cyclophosphamide, and autologous stem cell transplantation. Biol Blood Marrow Transplant 2006, 12:1343-1349.